<DOC>
	<DOC>NCT00481117</DOC>
	<brief_summary>This study intends to evaluate how safe and well tolerated the LY2405319 compound is when given to people for 7 days (in Part 1) and 28 days (in Part 2). This study intends to also determine if there is a positive effect on lowering the level of glucose in people with type 2 diabetes.</brief_summary>
	<brief_title>Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>Subjects in Part 1 will be randomized to receive LY2405319 or placebo over 7 days in one of 4 dose level groups, in ascending order: 1 mg, 3 mg, 10 mg, or 20 mg. Subjects in Part 2 will be randomized to receive LY2405319 or placebo over 28 days, and will receive the dose level determined to be the most well tolerated in Part 1.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Men and women without child bearing capability Ages 35 to 70 years Type 2 diabetic subjects, diagnosed for at least 3 months Average body weight (relative to height) Willing to be available for the duration of the study Significant medical illnesses (except Type 2 diabetes) Abnormal 12lead electrocardiogram (ECG ) Current or previous use of insulin for greater than 7 days for control of diabetes Regular use of drugs of abuse Excessive alcohol use</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>